

## ASX ANNOUNCEMENT

### CLOSURE OF OFFER UNDER THE SHARE PURCHASE PLAN

16<sup>th</sup> August 2019

Melbourne, Australia: Regenerative medicine company Exopharm Limited (“Exopharm” or the “Company”; ASX:EX1) wishes to advise that the offer to eligible shareholders under the share purchase plan (SPP) has now closed. Details of the SPP was announced to the market on 24<sup>th</sup> July 2019 and an SPP offer booklet was dispatched to eligible shareholders on 25<sup>th</sup> July 2019.

The Company is pleased to announce that a total of \$1,099,640 was raised under the SPP. Accordingly, a total of 2,972,000 fully paid ordinary shares at an offer price of \$0.37 per share will be issued to the eligible shareholders who participated in the SPP, which is expected to occur on or before 20<sup>th</sup> August 2019.

The Board wishes to thank its existing shareholders for their ongoing support and participation in the SPP.

As a result of the SPP, the capital structure of the Company will be:

#### Forecast Capital Structure

Description	Shares (FPO)
Existing Shares	92,400,000
SPP	2,972,000
Total shares after SPP	95,372,000
Director Placement Shares subject to shareholder approval	100,000
Total shares post SPP and shareholder approval	95,472,000

The funds raised under the SPP will be used to accelerate Exopharm’s development activities across manufacturing, testing and development of additional intellectual property – each aimed at validating Exopharm’s products and technologies and attracting partnership deals.

ENDS.

## **ABOUT EXOPHARM**

Exopharm Limited (“Exopharm” or the “Company”) (ASX:EX1) is a clinical stage Australian regenerative medicine biopharmaceutical company seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Exomeres™.

These products are exosomes that are derived from human platelets in relation to Plexaris, and adult stem cells in relation to Exomeres, and purified using the LEAP Technology and referred to as biologic products.

As its primary focus, Exopharm aims to be a leader in the field of human therapeutics using exosomes as regenerative medicine products for health span related conditions.

The Development Program: The Company’s main objectives for the next 12 months are to complete the following stages of its Development Program:

1. manufacturing - make and supply clinical grade autologous Plexaris product and development of the Exomere manufacturing process;
2. clinical use - initial small-scale human clinical studies of autologous Plexaris in wound healing;
3. supporting research and development activities - conducting research activities to support the ongoing Development Program and the development of related intellectual property; and
4. to also investigate other LEAP Technology Opportunities.

## **FORWARD LOOKING STATEMENTS**

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘aims’, ‘plans’ or ‘expects’. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm’s control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.